TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06587893

Intervention type: OTHER
Intervention: echography
Description: performance of ultrasound of the scapular regions to identify and measure the suprascapular notch in our group of healthy adult volunteers.
Study: NCT06602505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A: Field Block Group
Description: Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
Study: NCT06604208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binaural Beats
Description: The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06591104

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urinary protein
Description: proteinuria and renal function impairment will be detected in patients of four groups

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urinary protein
Description: proteinuria and renal function impairment will be detected in patients of four groups

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urinary protein
Description: proteinuria and renal function impairment will be detected in patients of four groups

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urinary protein
Description: proteinuria and renal function impairment will be detected in patients of four groups
Study: NCT06602804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel Auto RBC Collection
Description: This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.
Study: NCT06604182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based Simplified HCV Testing and Treatment Algorithm
Description: The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
Study: NCT06654882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNFi (Tumor Necrosis Factor inhibitor) medication
Description: Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: 10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: \<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: 10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID
Study: NCT06655454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental Postoperative Bupivacaine
Description: This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: This intervention will appear to give patients an additional injection, but no additional drug will be given.
Study: NCT06597721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-754
Description: Administered intravenously
Study: NCT05134077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT scan with contrast
Description: CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan with contrast
Description: CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Nephroscintigraphy
Description: Nephroscintigraphy is necessary to determine the renal function

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Nephroscintigraphy
Description: Nephroscintigraphy is necessary to determine the renal function
Study: NCT06261164

Intervention type: DEVICE
Intervention: Cytosorb® and Oxiris® adsorbents
Description: The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Intervention type: DEVICE
Intervention: Cytosorb® and Oxiris® adsorbents
Description: The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
Study: NCT06593392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difelikefalin
Description: The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
Study: NCT06587672

Intervention type: DEVICE
Intervention: Micra AV implantation
Description: Patients received Micra AV implantation
Study: NCT06586866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
Study: NCT06598163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Five Lives MED
Description: Five Lives MED is a mobile application that can be installed on smartphones and tablets using the Android and/or iOS operating systems for use at home.~The app offers structured sessions that can be completed once per day. Once the session is completed, the app also offers optional access to additional cognitive training exercises and educational articles.~The intervention sessions begins with a Habit Quest, a physical activity habit building tool delivered through a chat bot. Following the Habit Quest, the participant is guided through a series of gamified cognitive training exercises aimed at improving attention, memory, language and executive function.
Study: NCT05156567

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep Learning System
Description: The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
Study: NCT06601725

Intervention type: DIAGNOSTIC_TEST
Intervention: Clusterin level
Description: Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Clusterin level
Description: Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Clusterin level
Description: Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Clusterin level
Description: Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Study: NCT06598657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with Movement MWM
Description: Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: * Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week
Study: NCT06604637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)
Description: taVNS will be applied for a total of 12 sessions, 20 minutes each session, 3 days/week.
Study: NCT06599437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
Study: NCT06592105

Intervention type: PROCEDURE
Intervention: Endovascular aortic aneurysm repair (EVAR)
Description: Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
Study: NCT06603545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital education for osteoporosis patients
Description: DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
Study: NCT06588998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xengenic Cortical membranes
Description: soft tissue surgery around dental implant dehiscence

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: soft tissue surgery around dental implant dehiscence
Study: NCT06592950

Intervention type: OTHER
Intervention: No treatment given
Description: Online survey

Intervention type: OTHER
Intervention: No treatment given
Description: Interviews
Study: NCT06590714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental(Acelex cap m2mg)
Description: Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)
Description: NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Study: NCT06587646

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Examination under Anaeastehtic - 3D reconstruction imaging
Description: 3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care - Written MRI report
Description: A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
Study: NCT06586463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinitic control training
Description: kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinitic control training
Description: kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation.
Study: NCT06590896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate will be orally administered once daily.
Study: NCT06591533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy + standard care
Description: In the pre-extubation and extubation phase, the musical characteristics will be based on a slow to medium tempo, simple harmonic structures (e.g., tonic-subdominant movements), fluid melodies, and avoiding large intervals or abrupt changes of tonalities. The musical instruments used will be a classical guitar with nylon strings (Yamaha C-40) and the voice of the music therapist without lyrics or words. In the post-extubation phase, the musical characteristics will be based on a moderate tempo, introducing chord progressions aiming at tension-resolution (e.g., dominant-tonic), and a more rhythmic application of melodic or harmonic material.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care (in control arm)
Description: Standard care during the extubation process involves providing usual the medical care provided for patients according to each hospital's guidelines.
Study: NCT06595524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness-based intervention
Description: The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
Study: NCT06586632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AID technology
Description: Automated insulin delivery system combined with a CGM

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CGM
Description: CGM alone
Study: NCT06600828

Intervention type: OTHER
Intervention: Data collection
Description: Data collected: Socio-demographic, hospital, clinical, biological, and imaging data

Intervention type: OTHER
Intervention: Data collection
Description: Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
Study: NCT06589856

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
Study: NCT06598488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice placebo
Description: Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
Study: NCT06600698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INM176
Description: The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.
Study: NCT06597162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education of patient safety
Description: For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group.
Study: NCT06593197

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apremilast with NB-UVB
Description: Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: NBUVB only will be given twice per week for 8 months